Actively Recruiting
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Led by Washington University School of Medicine · Updated on 2026-02-20
100
Participants Needed
1
Research Sites
396 weeks
Total Duration
On this page
Sponsors
W
Washington University School of Medicine
Lead Sponsor
R
Roche Sequencing Solutions
Collaborating Sponsor
AI-Summary
What this Trial Is About
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
CONDITIONS
Official Title
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eligible healthy donors must be at least 18 years old
You will not qualify if you...
- Healthy donors younger than 18 years old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
M
Melissa Reimers, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here